Core Viewpoint - Company maintains "outperforming the industry" rating for CSPC Pharmaceutical Group (01093), citing improvements in its prescription drug business and strong growth in respiratory and cardiovascular sectors [1] Performance Summary - Company reported 1-3Q25 revenue of 19.891 billion, down 12.3% YoY, and net profit attributable to shareholders of 3.511 billion, down 7.1% YoY, with adjusted net profit of 3.079 billion, down 23.0% YoY, aligning with expectations [1] - 3Q25 revenue reached 6.618 billion, showing a 3.4% YoY increase and a 5.7% QoQ increase, indicating stabilization in performance [1] - Prescription drug revenue in 3Q25 was 5.202 billion, with a YoY increase of 1.6% and a QoQ increase of 9.6% [1] - Breakdown of 3Q25 prescription drug revenue: - Neurological diseases: 1.914 billion (YoY -4.2%) - Oncology: 0.594 billion (YoY -47.2%) - Anti-infection: 0.826 billion (YoY -8.6%) - Cardiovascular: 0.474 billion (YoY +17.8%) - Respiratory: 0.320 billion (YoY +72.7%) - Digestive: 0.248 billion (YoY +13.7%) - Other fields: 0.362 billion (YoY +25.6%) [1] - Raw material drug revenue in 3Q25 was 1.415 billion, up 10.5% YoY but down 6.4% QoQ [1] R&D Summary - Company continues to drive innovation with ongoing development of its small nucleic acid pipeline, with PCSK9 expected to enter Phase III by the end of 2025 [2] - Other clinical projects include LPa, AGT, ANGPTL3, and C5, targeting key chronic diseases such as dyslipidemia and hypertension [2] - Company is also exploring targeted delivery for eye, lung, fat, and muscle applications [2] - Key pipeline products include Anlotinib (HER2 bispecific), SYS6010 (EGFR ADC), and SYS6091 (HER2 ADC), all progressing well [2] Overseas Business Development Summary - Company is enhancing its business development strategy and building an international licensing platform [3] - In 1-3Q25, the company achieved licensing revenue of 1.540 billion, with a significant deal involving the licensing of SYH2086 (oral small molecule GLP-1) to Madrigal Pharmaceuticals, including a $120 million upfront payment and potential milestones of up to $1.955 billion [3] - The company has several innovative products in its pipeline, such as EGFR ADC and SiRNA series, which are expected to lead to more licensing agreements and milestone revenue recognition [3] Profit Forecast and Valuation - Due to increased R&D investment, the company has lowered its net profit forecasts for 2025 and 2026 by 12% and 15% to 4.760 billion and 5.353 billion, respectively [4] - Current stock price corresponds to a P/E ratio of 17.1x for 2025 and 15.0x for 2026 [4] - The company maintains its outperforming rating while reducing the target price by 15% to HKD 11.00, reflecting a P/E of 24.4x and 21.4x for 2025 and 2026, respectively, indicating a potential upside of 42.5% [4]

Core Viewpoint - The stock price of CSPC Pharmaceutical Group (01093) dropped over 6% following the release of its third-quarter results, reflecting market concerns over declining revenue and profit margins [1] Financial Performance - For the first three quarters, the company reported revenue of 19.891 billion RMB, a year-on-year decrease of 12.32% [1] - The profit attributable to the company's owners was 3.511 billion RMB, down 7.06% compared to the previous year [1] Business Segment Analysis - The prescription drug business generated revenue of 15.450 billion RMB, representing a year-on-year decline of 17.2% [1] - The decline in revenue is primarily attributed to the ongoing impact of centralized drug procurement and price adjustments in the national medical insurance drug list [1]

Core Viewpoint - The stock price of CSPC Pharmaceutical Group (01093) dropped over 6% following the release of its Q3 earnings report, reflecting ongoing challenges in the pharmaceutical industry due to policy impacts on drug pricing and procurement [1] Financial Performance - For the first three quarters, the company reported a revenue of 19.891 billion RMB, a year-on-year decrease of 12.32% [1] - The profit attributable to shareholders was 3.511 billion RMB, down 7.06% compared to the previous year [1] - The revenue from the prescription drug business was 15.450 billion RMB, which represents a year-on-year decline of 17.2% [1] Industry Impact - The decline in revenue is primarily attributed to the ongoing effects of centralized drug procurement and adjustments in the National Medical Insurance drug list pricing policies [1]

Core Insights - Three innovative drugs have made significant progress, potentially stabilizing the Hang Seng Biotechnology Index and the Hang Seng Innovative Drug Index [1] Group 1: Drug Developments - Innovent Biologics announced that its drug IBI362 (Mastuzumab Injection) has achieved primary and all key secondary endpoints in a Phase III clinical trial for moderate to severe obesity in China, with plans to submit a new drug application for weight control [1] - Junshi Biosciences' PD-1 inhibitor, H drug (Surulitinib), has been officially included in the NMPA's list of breakthrough therapies for perioperative treatment of gastric cancer, marking it as the first drug recognized for this indication [2] - Peijia Medical's PB-119 has received approval from the NMPA for its new drug application, leveraging unique PEGylation technology to enhance efficacy while reducing immunogenicity and gastrointestinal side effects [3] Group 2: Industry Trends - The introduction of the innovative drug directory by commercial insurance is expected to address the accessibility and affordability of high-priced innovative drugs, with policies increasingly favoring the development of high-quality innovative drugs [3] - Chinese innovative pharmaceutical companies are increasingly focusing on internationalization, transitioning from imitation to innovation, supported by favorable policies and abundant clinical resources [2][3] - The ongoing drug review reforms are releasing dividends that are propelling the Chinese innovative drug industry into a new era of "innovation output" [2]

Group 1 - Three innovative drugs have made significant progress, potentially stabilizing the Hang Seng Biotechnology Index and the Hang Seng Innovative Drug Index [1] - Innovent Biologics announced that its drug IBI362 has achieved primary and all key secondary endpoints in a Phase III clinical trial for obesity, with plans to submit a new drug application for weight control [1] - The drug IBI362 is a dual receptor agonist for glucagon and GLP-1, and is the first of its kind approved globally for obesity and type 2 diabetes management [1] Group 2 - Junshi Biosciences' PD-1 inhibitor, H drug, has been officially included in the breakthrough therapy list by the NMPA for use in perioperative treatment of gastric cancer, marking a significant recognition of its clinical value [2] - This breakthrough designation is expected to accelerate the review and approval process for H drug, filling a gap in immune therapy for gastric cancer [2] - The approval of PB-119 by the NMPA highlights the competitive advantage of the drug based on solid clinical data and innovative PEGylation technology, which balances efficacy and reduces side effects [1][3] Group 3 - The introduction of the innovative drug directory by commercial insurance is expected to address the accessibility and affordability of high-priced innovative drugs [3] - The National Healthcare Security Administration is encouraging the high-quality development of innovative drugs, indicating a warming trend in payment policies for innovative drugs [3] - Domestic pharmaceutical companies are actively transitioning towards innovation, supported by ongoing reforms in drug approval processes [3] Group 4 - Relevant Hong Kong stocks in the innovative drug sector include Heng Rui Medicine, Kelun-Botai Biopharmaceutical, and others, indicating a growing interest in the market [4]

Major Events - Sanofi Pharmaceutical (01530) proposes to spin off Mandi International and independently list it on the main board of the Hong Kong Stock Exchange [1] - Youbao Online (02429) signs a trusted asset management platform service agreement with Ant Chain Technology [1] - Jianxi Technology-B (09877) reports 6-month clinical follow-up results for LuX-Valve Plus TRINITY study on patients with large valve rings [1] - Fuhong Hanlin (02696) announces that Hanshu® (Sru Li monoclonal antibody injection) combined with chemotherapy for gastric cancer neoadjuvant/adjuvant treatment has been officially included in the breakthrough therapy drug program by the National Medical Products Administration [1] - Kaizhile International (02122) partners with globally renowned toy company Jazwares to launch HELLO KITTY AND FRIENDS toys [1] Operating Performance - ZTO Express-W (02057) reports third-quarter net profit attributable to shareholders of 2.524 billion yuan, an increase of 5.32% year-on-year [1] - Lenovo Group (00992) announces interim results with a profit attributable to shareholders of 846 million USD, a year-on-year growth of 40% [1] - CSPC Pharmaceutical Group (01093) releases third-quarter results showing a profit attributable to shareholders of 3.511 billion yuan, a decrease of 7.06% year-on-year [1] - NetEase-S (09999) reports third-quarter net profit attributable to shareholders of approximately 8.616 billion yuan, a year-on-year increase of 31.77%, with a dividend of 0.114 USD per share [1] - Jingyou Pharmaceutical (00858) issues a profit warning, expecting a mid-term loss of approximately 450 million to 480 million HKD, transitioning from profit to loss year-on-year [1]

Core Viewpoint - The Hong Kong stock market continues to adjust, with the Hang Seng Index showing mixed performance, while the innovative drug sector demonstrates resilience, as evidenced by the performance of the Hong Kong Stock Connect Innovative Drug ETF (520880) which ended a four-day decline [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) saw a price increase of 1.79% during the day, successfully ending its previous four-day decline [1]. - The ETF's performance is supported by major leading stocks in the innovative drug sector, with notable gains from companies such as Innovent Biologics, which rose by 2.84%, and others like China Biologic Products and Kintor Pharmaceutical, which increased by over 1% [1]. Group 2: Investment Insights - Following a strong rebound of nearly 7% the previous week, the ETF has returned to a state of fluctuation, currently trading at a near four-month low, indicating a potential area for cost-effective investment [3]. - The fund manager, Feng Chen, suggests that each significant pullback in the innovative drug sector presents an opportunity for accumulation [3]. - The innovative drug sector is undergoing a notable correction since early September, attributed to market style shifts and the return to more realistic expectations regarding business development (BD) rhythms and amounts [3]. Group 3: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) is characterized by three unique advantages: it is purely focused on innovative drug companies, has a significant concentration of leading stocks with over 71% weight in the top ten holdings, and maintains better risk control by reducing the weight of less liquid component stocks [3][4]. - The top ten holdings in the ETF account for 71.51% of the total weight, showcasing the dominance of leading companies in the sector [4]. - As of November 19, the ETF has a scale of 2.12 billion HKD and an average daily trading volume of 464 million HKD since its inception, making it the largest and most liquid ETF tracking the same index [4].

Investment Rating - The industry investment rating is "Outperform" [31] Core Insights - Pfizer's Q3 2025 revenue decreased from $17.7 billion to $16.65 billion, a decline of 7% year-over-year, primarily due to reduced demand for COVID-19 products [3][10] - Despite the revenue drop, Pfizer raised its full-year profit forecast, driven by growth in non-COVID business segments [3] - Total revenue for the first three quarters of 2025 was $45.02 billion, down 2% year-over-year [3][10] Summary by Sections Part 1: Q3 2025 Financial Overview and Key Events - Pfizer's Q3 2025 reported net income was $3.54 billion, a 21% decrease from the previous year, while adjusted income was $4.95 billion, down 18% [7][10] - Key events included reaching an agreement with the U.S. government to alleviate tariff threats and a partnership with Metsera to enhance its presence in the obesity market [13][11] Part 2: Core Product Sales Analysis - The oncology segment is the fastest-growing among Pfizer's three business units, with Ibrance sales at $3.083 billion, down 6% year-over-year [20] - Nectin-4 ADC drug Padcev generated $464 million in Q3 2025, a 13% increase, and is established as a standard treatment for certain cancers [20][29] - Rare disease drug Vyndaqel series sales reached $1.591 billion, up 7%, benefiting from ongoing promotion in developed markets [20] Part 3: Future Pipeline Milestones - Pfizer anticipates one regulatory decision and two Phase III data readouts potentially delayed to 2026 [23][25] - The regulatory decision involves BRAFTOVI for treating BRAF V600E mutation metastatic colorectal cancer [25]

Core Insights - The company reported a decline in revenue and net profit for the first three quarters of 2025, with total revenue at RMB 19.89 billion, down 12.3% year-on-year, and net profit attributable to shareholders at RMB 3.511 billion, down 7.1% [1] Financial Performance - Total revenue for the first three quarters was RMB 19.89 billion, a decrease of 12.3% compared to the previous year [1] - Net profit attributable to shareholders was RMB 3.511 billion, reflecting a year-on-year decline of 7.1% [1] - Adjusted net profit was RMB 3.079 billion, down 23% year-on-year [1] - Basic earnings per share were RMB 0.3072, a decrease of 4.1% from the same period last year [1] Business Segments - Revenue from the pharmaceutical business was RMB 15.45 billion, down 17.2%, primarily due to centralized procurement and price adjustments in the national medical insurance drug list [1] - Revenue from raw material products was RMB 3.006 billion, an increase of 10.3%, with vitamin C sales reaching RMB 1.788 billion, up 22.3% [1] - Revenue from functional foods and other businesses was RMB 1.435 billion, reflecting an 11.2% increase [1] Research and Development - R&D expenses increased by 7.9% to RMB 4.185 billion, accounting for 27.1% of pharmaceutical business revenue [2] - The company has nearly 90 products in various stages of clinical trials, with 14 submitted for market approval and over 30 key products in the registration clinical phase [2]

格隆汇11月20日｜石药集团(01093.HK)公布，2025年首九个月，集录得收入人民币198.91亿元及公司股 东应占呈报溢利人民币35.11亿元，分别较去年同期减少12.3%及7.1%。撇除按公平值计入损益之金融资 产的公平值变动及以股份为基础之雇员酬金开支后，公司股东应占基本溢利为人民币30.79亿元，较去 年同期减少23.0%。公司股东应占呈报溢利的每股基本盈利为人民币30.72分，较去年同期减少4.1%。 来源：格隆汇APP ...